T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.45B |
| 2 |
Pinterest
PINS
|
+$1.89B |
| 3 |
T-Mobile US
TMUS
|
+$1.89B |
| 4 |
Zoom
ZM
|
+$1.77B |
| 5 |
UiPath
PATH
|
+$1.71B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$3.66B |
| 2 |
Caterpillar
CAT
|
+$1.32B |
| 3 |
Netflix
NFLX
|
+$1.18B |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$1.15B |
| 5 |
Micron Technology
MU
|
+$1.07B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.71% |
| 2 | Healthcare | 16.11% |
| 3 | Consumer Discretionary | 15.3% |
| 4 | Communication Services | 13.46% |
| 5 | Financials | 12.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KYNB
1376
Kyntra Bio
KYNB
$28.8M
| $13.2M | ﹤0.01% |
19,859
-56,064
| -74% | -$32.3M |
|
1377
SiTime
SITM
$21B
| $13.1M | ﹤0.01% |
103,862
-18,543
| -15% | -$1.89M |
|
|
CMRX
1378
DELISTED
Chimerix, Inc.
CMRX
| $13.1M | ﹤0.01% |
1,632,612
-106,257
| -6% | -$884K |
|
1379
Stoke Therapeutics
STOK
$2B
| $13M | ﹤0.01% |
387,423
-235,769
| -38% | -$8.33M |
|
1380
Celldex Therapeutics
CLDX
$3.23B
| $13M | ﹤0.01% |
389,048
+56,818
| +17% | +$1.56M |
|
|
ISEE
1381
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $13M | ﹤0.01% |
2,052,740
-110,452
| -5% | -$713K |
|
|
TPH
1382
DELISTED
Tri Pointe Homes
TPH
| $12.7M | ﹤0.01% |
592,423
-1,695,056
| -74% | -$38.8M |
|
1383
Genpact
G
$5.71B
| $12.7M | ﹤0.01% |
278,975
+2,112
| +0.8% | +$95.6K |
|
1384
Bumble
BMBL
$358M
| $12.6M | ﹤0.01% |
218,622
+700
| +0.3% | +$36.9K |
|
|
SBT
1385
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $12.4M | ﹤0.01% |
2,733,300
-15,533
| -0.6% | -$75.5K |
|
1386
AMC Entertainment Holdings
AMC
$2.27B
| $12.4M | ﹤0.01% |
21,852
+8,791
| +67% | +$2.33M |
|
|
INFN
1387
DELISTED
Infinera Corporation Common Stock
INFN
| $12.3M | ﹤0.01% |
1,207,529
+61,716
| +5% | +$598K |
|
1388
Sixth Street Specialty
TSLX
$1.79B
| $12.3M | ﹤0.01% |
555,000
| – | – |
|
|
CTRA
1389
DELISTED
Coterra Energy
CTRA
| $12.2M | ﹤0.01% |
696,527
-17,498
| -2% | -$298K |
|
1390
Vornado Realty Trust
VNO
$7.28B
| $12.1M | ﹤0.01% |
259,145
-1,722
| -0.7% | -$80.5K |
|
1391
AtaiBeckley Inc
ATAI
$2.69B
| $12M | ﹤0.01% |
+650,000
| New | +$12M |
|
1392
PUT
Bath & Body Works
BBWI
$3.89B
| $11.8M | ﹤0.01% |
+20,287
| New | +$1.1M |
|
1393
Guidewire Software
GWRE
$14.7B
| $11.7M | ﹤0.01% |
104,128
-14,886
| -13% | -$1.55M |
|
|
PBCT
1394
DELISTED
People's United Financial Inc
PBCT
| $11.6M | ﹤0.01% |
678,044
+2,900
| +0.4% | +$53K |
|
1395
Kforce
KFRC
$1.05B
| $11.6M | ﹤0.01% |
184,621
+160,343
| +660% | +$9.49M |
|
1396
Invitation Homes
INVH
$18.1B
| $11.6M | ﹤0.01% |
309,854
-15,591
| -5% | -$551K |
|
1397
Leggett & Platt
LEG
$1.32B
| $11.5M | ﹤0.01% |
222,432
-4,490
| -2% | -$234K |
|
1398
Prelude Therapeutics
PRLD
$433M
| $11.5M | ﹤0.01% |
400,802
-22,189
| -5% | -$790K |
|
1399
Enanta Pharmaceuticals
ENTA
$380M
| $11.1M | ﹤0.01% |
252,782
-611,479
| -71% | -$29.9M |
|
1400
United Therapeutics
UTHR
$21.4B
| $11M | ﹤0.01% |
61,255
-292,869
| -83% | -$55.8M |
|
Similar funds
T. Rowe Price Associates's Q2 2021 Portfolio in Review
As of Q2 2021, T. Rowe Price Associates held 3,000 positions worth $1.08T, up 8% from $999B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2021 filing shows 159 new, 1,164 increased, 1,499 reduced and 84 closed positions. Its largest new stake was UiPath: 23,377,090 shares worth $1.52B. The largest sale was Alibaba, an estimated $3.66B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2021 buy was UiPath: 23,377,090 shares worth $1.52B.
- T. Rowe Price Associates added most to Microsoft in Q2 2021, an estimated $3.45B increase.
- T. Rowe Price Associates's biggest Q2 2021 reduction was Alibaba, cutting an estimated $3.66B.
- T. Rowe Price Associates fully exited Pershing Square Tontine Holdings, Ltd. in Q2 2021, selling an estimated $145M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.08T portfolio in Q2 2021.
- T. Rowe Price Associates opened 159 new positions and closed 84 in Q2 2021.
- T. Rowe Price Associates's portfolio value rose 8% quarter-over-quarter to $1.08T.
Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.